Is CNCE or DGRO a better dividend investment in 2026?

CNCE currently yields 23.89% with a 5% 5-year dividend growth rate. DGRO yields 2.13% with 9.5% growth. The better choice depends on your goal: CNCE offers higher current income.

What is the dividend yield difference between CNCE and DGRO?

CNCE has a forward dividend yield of 23.89% ($2.00/share annually). DGRO yields 2.13% ($1.47/share annually). The yield gap is 21.76 percentage points.

Home › Compare › CNCE vs DGRO

CNCE vs DGRO: Dividend Comparison 2026

CNCE yields 23.89% · DGRO yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CNCE wins by $60.8K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CNCE

● Live price

23.89%

Share price

$8.37

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$92.5K

Annual income

$10,014.51

Full CNCE calculator →

DGRO

iShares Core Dividend Growth ETF

● Live price

2.13%

Share price

$68.98

Annual div

$1.47

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.6K

Annual income

$239.96

Full DGRO calculator →

Portfolio growth — CNCE vs DGRO

📍 CNCE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CNCE	DGRO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CNCE + DGRO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CNCE pays

DGRO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNCE

Annual income on $10K today (after 15% tax)

$2,031.06/yr

After 10yr DRIP, annual income (after tax)

$8,512.33/yr

DGRO

Annual income on $10K today (after 15% tax)

$181.24/yr

After 10yr DRIP, annual income (after tax)

$203.97/yr

At 15% tax rate, CNCE beats the other by $8,308.37/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNCE + DGRO for your $10,000?

CNCE: 50%DGRO: 50%

100% DGRO50/50100% CNCE

Portfolio after 10yr

$62.0K

Annual income

$5,127.24/yr

Blended yield

8.26%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CNCE right now

CNCE

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

2.4

Piotroski

1/9

DGRO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNCE buys

DGRO buys

No recent congressional trades found for CNCE or DGRO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCNCEDGRO

Forward yield	23.89% ✓	2.13%
Annual dividend / share	$2.00 ✓	$1.47
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$92.5K ✓	$31.6K
Annual income after 10y	$10,014.51 ✓	$239.96
Total dividends collected	$57.3K ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CNCE vs DGRO ($10,000, DRIP)

Year	CNCE Portfolio	CNCE Income/yr	DGRO Portfolio	DGRO Income/yr	Gap
1← crossover	$13,089	$2,389.49	$11,293	$213.22	+$1.8K → CNCE
2	$16,929	$2,923.10	$12,730	$217.32	+$4.2K → CNCE
3	$21,647	$3,533.17	$14,326	$221.10	+$7.3K → CNCE
4	$27,385	$4,222.32	$16,098	$224.56	+$11.3K → CNCE
5	$34,294	$4,992.02	$18,064	$227.74	+$16.2K → CNCE
6	$42,537	$5,842.50	$20,246	$230.65	+$22.3K → CNCE
7	$52,287	$6,772.75	$22,666	$233.30	+$29.6K → CNCE
8	$63,728	$7,780.57	$25,349	$235.73	+$38.4K → CNCE
9	$77,051	$8,862.62	$28,325	$237.94	+$48.7K → CNCE
10	$92,459	$10,014.51	$31,624	$239.96	+$60.8K → CNCE

CNCE vs DGRO: Complete Analysis 2026

CNCE — Stock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Full CNCE Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →

📬

Get this CNCE vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNCE vs SCHD CNCE vs JEPI CNCE vs O CNCE vs KO CNCE vs MAIN CNCE vs VIG CNCE vs NOBL CNCE vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.